ftc News
Most Popular ftc Story
Medicis wins anti-wrinkle drug Reloxin in licensing pact
Medicis may have been out-bid in its effort to buy Inamed, but it looks like it will end up with the most sought-after prize in the acquisition after all. With Allergan poised to go ahead with its $3.2 billion acquisition of Inamed, Medicis licensed the experimental anti-wrinkle drug Reloxin from Ipsen. The FTC has agreed to approve the buyout provided Inamed returns the development rights to Reloxin to France's Ipsen. Medicis says that Reloxin promises to get through the FDA approval …
... Read more...Latest Headlines
- March 31, 2008
- December 5, 2007
- January 18, 2007
- July 9, 2006
- June 26, 2006
- April 24, 2006
- March 29, 2006
- March 13, 2006
- November 7, 2005
- November 2, 2005
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
